Lesion selection and external evaluation of clinical-imaging survival models after transarterial chemoembolization for hepatocellular carcinoma

Background: Pretreatment computed tomography (CT) describes tumor characteristics in patients receiving transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC), but whether measuring more tumors improves mortality predictions in a new cohort remains unclear. We assessed the added value of different lesion-selection scopes beyond shared clinical predictors. Methods: We compared a model using five clinical variables with models adding CT measurements from the largest, two largest, or all retained annotated tumors. All models used the same regularized discrete-time survival esti

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.